Tags

Type your tag names separated by a space and hit enter

Selective removal of clonogenic neoplastic B cells from human bone marrow using anti-HLA-DQ antibodies and complement.
Exp Hematol. 1986 Feb; 14(2):101-7.EH

Abstract

Polymorphic HLA-DQ (DC/MB) determinants appeared to be not expressed on human hematopoietic progenitor cells (HPC), using several murine monoclonal and human polyclonal antibodies in a complement-dependent cytotoxicity (CDC) assay. Since mature HLA-DR-positive malignant lymphoma cells prove to be HLA-DQ positive, an attempt was made to remove clonogenic neoplastic DQwl-positive B cells selectively from DQwl-positive marrow samples without affecting hematopoietic progenitor cells. Using a combination of a clonogenic tumor cell assay, an HPC culture assay, and a mixed-tumor-cell-HPC culture assay, selective elimination of more than 98% of clonogenic neoplastic cells from tumor-cell-contaminated bone marrow suspensions was achieved with monoclonal anti-DQ antibodies and complement without depletion of HPC. These results indicate that anti-HLA-DQ antibodies can be used in autologous bone marrow transplantation to deplete the bone marrow cell suspension of DQ-positive malignant cells.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

2417877

Citation

Falkenburg, J H., et al. "Selective Removal of Clonogenic Neoplastic B Cells From Human Bone Marrow Using anti-HLA-DQ Antibodies and Complement." Experimental Hematology, vol. 14, no. 2, 1986, pp. 101-7.
Falkenburg JH, Fibbe WE, Veenhof WF, et al. Selective removal of clonogenic neoplastic B cells from human bone marrow using anti-HLA-DQ antibodies and complement. Exp Hematol. 1986;14(2):101-7.
Falkenburg, J. H., Fibbe, W. E., Veenhof, W. F., Koning, F., van Eeden, G., Voogt, P. J., & Jansen, J. (1986). Selective removal of clonogenic neoplastic B cells from human bone marrow using anti-HLA-DQ antibodies and complement. Experimental Hematology, 14(2), 101-7.
Falkenburg JH, et al. Selective Removal of Clonogenic Neoplastic B Cells From Human Bone Marrow Using anti-HLA-DQ Antibodies and Complement. Exp Hematol. 1986;14(2):101-7. PubMed PMID: 2417877.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Selective removal of clonogenic neoplastic B cells from human bone marrow using anti-HLA-DQ antibodies and complement. AU - Falkenburg,J H, AU - Fibbe,W E, AU - Veenhof,W F, AU - Koning,F, AU - van Eeden,G, AU - Voogt,P J, AU - Jansen,J, PY - 1986/2/1/pubmed PY - 1986/2/1/medline PY - 1986/2/1/entrez SP - 101 EP - 7 JF - Experimental hematology JO - Exp Hematol VL - 14 IS - 2 N2 - Polymorphic HLA-DQ (DC/MB) determinants appeared to be not expressed on human hematopoietic progenitor cells (HPC), using several murine monoclonal and human polyclonal antibodies in a complement-dependent cytotoxicity (CDC) assay. Since mature HLA-DR-positive malignant lymphoma cells prove to be HLA-DQ positive, an attempt was made to remove clonogenic neoplastic DQwl-positive B cells selectively from DQwl-positive marrow samples without affecting hematopoietic progenitor cells. Using a combination of a clonogenic tumor cell assay, an HPC culture assay, and a mixed-tumor-cell-HPC culture assay, selective elimination of more than 98% of clonogenic neoplastic cells from tumor-cell-contaminated bone marrow suspensions was achieved with monoclonal anti-DQ antibodies and complement without depletion of HPC. These results indicate that anti-HLA-DQ antibodies can be used in autologous bone marrow transplantation to deplete the bone marrow cell suspension of DQ-positive malignant cells. SN - 0301-472X UR - https://www.unboundmedicine.com/medline/citation/2417877/Selective_removal_of_clonogenic_neoplastic_B_cells_from_human_bone_marrow_using_anti_HLA_DQ_antibodies_and_complement_ L2 - https://antibodies.cancer.gov/detail/CPTC-HLA-DPB1-2 DB - PRIME DP - Unbound Medicine ER -